摘要
目的探讨培美曲塞在晚期非小细胞肺癌姑息性化疗中的效果。方法66例晚期非小细胞肺癌患者,采用随机数字表法分为对照组和观察组,每组33例。两组患者均采用顺铂进行姑息性化疗治疗,在此基础上,对照组增加吉西他滨进行化疗,观察组增加培美曲塞进行化疗。比较两组患者短期疗效、化疗不良反应发生情况及治疗前后免疫功能指标。结果观察组患者总有效率60.61%(20/33)明显高于对照组的36.36%(12/33),差异具有统计学意义(P<0.05)。治疗后,观察组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于本组治疗前,CD8^(+)低于本组治疗前,且观察组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,差异具有统计学意义(P<0.05)。观察组化疗不良反应发生率18.18%(6/33)明显低于对照组的42.42%(14/33),差异具有统计学意义(P<0.05)。结论在晚期非小细胞肺癌姑息性化疗中应用培美曲塞效果较好,可以有效提高短期疗效,改善机体免疫力,减少化疗不良反应的发生,具有十分重要的临床应用价值,值得推荐患者选用。
Objective To discuss the effect of pemetrexed in palliative chemotherapy for advanced nonsmall-cell lung cancer.Methods A total of 66 patients with advanced non-small-cell lung cancer were divided into control group and observation group by random numerical table,with 33 cases in each group.Both groups were treated with cisplatin for palliative chemotherapy.On this basis,gemcitabine was added to chemotherapy in the control group,and pemetrexed was added to chemotherapy in the observation group.The short-term efficacy,occurrence of adverse chemotherapy reactions,and immune function indexes before and after treatment were compared between the two groups.Results The total effective rate 60.61%(20/33)in the observation group was significantly higher than 36.36%(12/33)in the control group,and the difference was statistically significant(P<0.05).After treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)of the observation group were higher than those of this group before treatment,and the CD8^(+)was lower than that of this group before treatment;the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)of the observation group were higher than those of the control group,and the CD8^(+)was lower than that of the control group.All differences were statistically significant(P<0.05).The incidence of adverse chemotherapy reactions 18.18%(6/33)in the observation group was was significantly lower than 42.42%(14/33)in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of pemetrexed in the palliative chemotherapy of advanced non-small-cell lung cancer is effective,which can effectively improve the short-term efficacy,improve the immunity of the body and reduce the occurrence of adverse chemotherapy reactions,and has a very important clinical application valu.It is worthy of recommendation.
作者
由金萍
YOU Jinping(General Hospital of Ansteel Group Corporation,Anshan 114000,China)
出处
《中国现代药物应用》
2022年第2期143-145,共3页
Chinese Journal of Modern Drug Application
关键词
培美曲塞
晚期非小细胞肺癌
姑息性化疗
免疫指标
不良反应
Pemetrexed
Advanced non-small-cell lung cancer
Palliative chemotherapy
Immune indicators
Adverse reactions
